LOUISVILLE, Colo., July 28, 2020 — Roy J. Bostock, former Chairman of Yahoo!, Vice Chairman of Delta Airlines and a director of Morgan Stanley, has joined the cellular medicine startup GID BIO…
GID BIO reaches halfway enrollment in randomized double-blinded pivotal Phase III cell therapy trial
FDA-compliant trial addresses treatment gap for regenerative medicine to potentially treat knee osteoarthritis…
We tapped Sandeep Samudre, PhD, MPH, to lead our trial operations including the pivotal trial for knee osteoarthritis and other efforts in our pipeline across…
Dr. Manish Gupta, an orthopaedic surgeon with a sports medicine focus enters as GID BIO’s newest principal investigator in a pivotal trial of the GID SVF-2…
In 2017, the Food and Drug Administration gave for-profit stem cell clinics three years to engage the regulatory approval process to establish the safety…
The proper surveillance of medical devices is necessary to ensure the health and safety of the public, and the Food and Drug Administration is committed…
GID BIO welcomes two new employees to the team as the newest of eight trial sites begin gearing up to enroll patients to participate in…
Tariq Awan, DO, a double-certified family and sports medicine physician with a special focus in sports medicine enters as GID BIO’s newest principal investigator in a pivotal Phase III trial evaluating cellular therapy for the treatment…
Listen to former NFL players Jaime Garza, MD, DDS, FACS, one of GID BIO’s principal investigators, and Jim Kovach, MD, JD, as they reunite on…
New trial site, the University of Pittsburgh Medical Center, joins GID BIO’s pivotal Phase III trial…
Charles De Mesa, DO, MPH, a Northern California practicing specialist in anesthesiology and pain medicine, physical medicine and rehabilitation and musculoskeletal pain medicine is GID Bio’s newest principal investigator in a pivotal trial…